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Summary 21	  
The AMP-activated protein kinase (AMPK) is a key regulator of energy balance expressed 22	  
ubiquitously in eukaryotic cells. Here, we review the canonical adenine nucleotide-dependent 23	  
mechanism that activates AMPK when cellular energy status is compromised, as well as other, non-24	  
canonical activation mechanisms. Once activated, AMPK acts to restore energy homeostasis by 25	  
promoting catabolic pathways, resulting in ATP generation, and inhibiting anabolic pathways that 26	  
consume ATP. We also review the various hypothesis-driven and unbiased approaches that have 27	  
been used to identify AMPK substrates, which have revealed substrates involved in both metabolic 28	  
and non-metabolic processes. We particularly focus on methods for identifying the AMPK target 29	  
recognition motif, and how it can be used to predict new substrates.  30	   	   	  31	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AMPK – subunit structure and regulation  32	  
The AMP-activated protein kinase (AMPK) is a key sensor of cellular energy status present in 33	  
essentially all eukaryotic cells, where it occurs as heterotrimers comprising catalytic α subunits and 34	  
regulatory β and γ subunits [1-3]. Genes encoding at least one of these subunits are found in the 35	  
genomes of essentially all eukaryotes, while mammals have genes encoding multiple isoforms (α1, 36	  
α2; β1, β2; γ1, γ2, γ3). AMPK heterotrimers are normally only significantly active after 37	  
phosphorylation of a conserved threonine residue within the activation loop of the α subunit kinase 38	  
domain (Thr172 in rat α2 [4]; the numbering may differ in other species). Mammalian AMPK is 39	  
activated through binding of 5'-AMP by three complementary effects (Fig. 1): i. promotion of 40	  
Thr172 phosphorylation by upstream kinases; ii. inhibition of Thr172 dephosphorylation by protein 41	  
phosphatases; and iii. allosteric activation. Although allosteric activation is only triggered by 42	  
binding of AMP, effect #1 (promotion of Thr172 phosphorylation [5]) and #2 (inhibition of Thr172 43	  
dephosphorylation [6, 7]) can be mimicked by ADP. Since ATP antagonizes these effects, AMPK 44	  
acts as a sensor of cellular AMP:ATP and ADP:ATP ratios, both of which increase during cellular 45	  
energy stress (although the changes in AMP:ATP are always larger due to the adenylate kinase 46	  
reaction [7]). AMPK can sense small changes in AMP even in the presence of concentrations of 47	  
ATP two to three orders of magnitude higher [7, 8]. 48	  
In this review, we will discuss recent studies of the molecular mechanisms by which AMPK is 49	  
activated by the canonical inputs AMP and ADP (introduced above), as well as by the non-50	  
canonical inputs that are being increasingly recognized. We also discuss recent approaches aimed at 51	  
establishing the full complement of downstream targets that are phosphorylated in cells when 52	  
AMPK is activated. 53	  
Canonical and non-canonical inputs into the AMPK system 54	  
Canonical inputs - adenine nucleotide binding to the AMPK-γ  subunit 55	  
AMPK senses changes in AMP through its direct binding to the γ subunit. AMPK-γ subunits in all 56	  
species contain four tandem repeats of sequence motifs known as cystathionine β-synthase (CBS) 57	  
repeats. These also occur in a small number of other proteins in the human genome, although 58	  
usually as just two tandem repeats. In many cases, each tandem pair of repeats bind a regulatory 59	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adenosine-containing ligand, such as ATP or S-adenosyl methionine, in the cleft between the 60	  
repeats [9]. In AMPK-γ subunits, the four repeats assemble into a disc-like shape with one repeat in 61	  
each quadrant, generating four potential nucleotide-binding sites that are numbered according to 62	  
which repeat binds the ribose ring of each nucleotide. Of these, site 2 appears to be always vacant, 63	  
while site 4 is thought to contain only a permanently-bound AMP [10]. Although the latter view has 64	  
been challenged [11], this would leave sites 1 and 3 as the sites where AMP, ADP and ATP bind in 65	  
competition. 66	  
 A crystal structure [8] of the human α1β2γ1 complex containing several bound ligands (AMP, 67	  
the kinase inhibitor staurosporine and the glycogen mimetic β-cyclodextrin) is shown in Fig. 2; it is 68	  
similar to previous structures of α2β1γ1 [12] and α1β1γ1 [13] complexes. The kinase domain on 69	  
the α subunit (α-KD), containing the small N-terminal and larger C-terminal lobes of a typical 70	  
protein kinase, is immediately followed by the autoinhibitory domain (α-AID), which is so-called 71	  
because KD:AID constructs are 10-fold less active than those containing the KD alone [14-16]. 72	  
Structures of KD:AID constructs from fission yeast [17], and human α1 [8], reveal the α-AID to be 73	  
a compact bundle of three α-helices that inhibits the kinase by binding of its helix α3 to the N- and 74	  
C- lobes of the α-KD, on the opposite surface to the active site (Fig. 3A). In all structures of active 75	  
kinase domains, four hydrophobic side chains known as the regulatory spine are stacked in 76	  
alignment, indicating the correct disposition of active site residues [18]. In the inactive KD:AID 77	  
structure shown in Fig. 3A, these residues (shown in white, red, magenta and blue) are not aligned. 78	  
By contrast, in the structures of active AMPK heterotrimers, the α-AID has rotated away from the 79	  
α-KD, with its α3 helix now interacting with the second CBS repeat of the γ subunit instead (Fig. 80	  
2), and the side chains of the regulatory spine are now aligned (e.g. Fig. 3B).  81	  
 The α-AID is connected to the C-terminal domain of the α-subunit (α-CTD) by a critical region 82	  
of extended polypeptide termed the α-linker. In the view of Fig. 2 this linker (shown in space-filling 83	  
representation in blue, red and magenta) wraps around the front face of the γ subunit. It contains 84	  
two conserved motifs, termed α-RIM1 and α-RIM2 (RIM = regulatory subunit interacting motif) 85	  
[19]. In structures of active heterotrimers, α-RIM1 (in blue in Fig. 2) binds to the surface of the γ 86	  
subunit containing the vacant site 2, while α-RIM2 (in magenta) interacts with site 3 containing 87	  
bound AMP. This tight association of the α-linker with the AMP-bound form of the γ subunit is 88	  
proposed to cause the observed rotation of the α-AID away from the α-KD, thus explaining how 89	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binding of AMP at site 3 causes allosteric activation [12, 19]. This model requires that binding of 90	  
ATP at site 3 would not allow the same interaction with α-RIM2. Supporting this, the interaction 91	  
between an α-AID:linker fragment and a construct containing the γ subunit was shown by 92	  
luminescence energy transfer to be enhanced by AMP binding, but decreased by ATP binding [8].  93	  
 Recent experiments with a novel AMPK activator suggest that the ability of AMP analogs to 94	  
protect against Thr172 dephosphorylation (effect #2) is also due to binding at site 3. C13 (see Fig. 95	  
4A) is a phosphonate diester that is taken up into cells and converted by cellular esterases to C2, a 96	  
potent AMP analog [20]. In cell-free assays, C2 promoted effects #2 (protection against Thr172 97	  
dephosphorylation) and #3 (allosteric activation) using α1-containing complexes, but in α2-98	  
containing complexes, it was only a partial allosteric agonist compared to AMP, and failed to 99	  
protect against Thr172 dephosphorylation. However, the full effects could be transferred to α2-100	  
containing complexes merely by replacing part of the α-linker from α2 (including α-RIM2) with 101	  
the equivalent region from α1 [21]. Since α-RIM2 contacts site 3, but no part of the α-linker 102	  
contacts sites 1 or 4 (which are on the opposite face of the γ subunit), binding of C2 at site 3 seems 103	  
to be crucial for effect #2 as well as #3. This leaves open the question of the functions, if any, of 104	  
AMP binding at sites 1 and 4. 105	  
 What is the exact mechanism for effect #2 (protection against Thr172 dephosphorylation)? 106	  
Current structures of the heterotrimer, which are in active conformations with AMP bound in site 3, 107	  
can be divided into two major regions termed the “catalytic module” (upper left in Fig. 2) and 108	  
“nucleotide-binding” module (lower right in Fig. 2), with Thr172 located in the cleft between them. 109	  
The α-linker can be regarded as a flexible connector linking these two modules, and its release from 110	  
the γ subunit when ATP replaces AMP at site 3 may allow the catalytic and nucleotide-binding 111	  
modules to move apart, increasing the accessibility of Thr172 to phosphatases, thus inducing 112	  
dephosphorylation [6]. This movement would also allow the α-AID to move back into its inhibitory 113	  
position behind the α-KD, thus reversing allosteric activation. In support of this model, 114	  
measurements of small angle X-ray scattering [22], and luminescence energy transfer [8] both 115	  
suggest that heterotrimers adopt less compact conformations when ATP, rather than AMP, is 116	  
bound. 117	  
 The explanation for effect #1 (promotion of Thr172 phosphorylation by LKB1) remains 118	  
unknown, although an intriguing recent proposal is that AMP binding causes AMPK to co-localize 119	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with LKB1 due to their mutual interactions with the scaffold protein axin, which in turn binds to 120	  
LAMTOR1 at the surface of the lysosome [23, 24]. However, effect #1 can also be observed on 121	  
reconstitution of highly purified LKB1 and AMPK [7], suggesting that it does not strictly require 122	  
these additional components. 123	  
Non-canonical inputs - activation by ligands that bind between the α and β subunits 124	  
Many screens of candidate molecules, as well as unbiased screens, have been conducted in the hunt 125	  
for AMPK activators that might have therapeutic potential. A small selection of known activators is 126	  
shown in Fig. 4. One class (Fig. 4A), including C13 [20] and 5-aminoimidazole-4-carboxamide 127	  
ribonucleoside (AICAR) [25], are pro-drugs converted by cellular enzymes into AMP analogs that 128	  
bind to the γ subunit. A second class (Fig. 4B) is exemplified by A-769662 [26], which does not 129	  
bind at the AMP-binding sites even though, like AMP, it causes both allosteric activation and 130	  
protection against Thr172 dephosphorylation [15, 27]. Binding of A-769662 involves the β-subunit 131	  
carbohydrate-binding module (β-CBM), which is related to non-catalytic domains found in 132	  
enzymes that metabolize glycogen or starch, and has been shown to cause binding of AMPK to 133	  
glycogen particles within cells [28, 29]. In the structure shown in Fig. 2, the synthetic 134	  
oligosaccharide β-cyclodextrin was bound at the presumed glycogen-binding site. In other recent 135	  
structural analyses [12, 13], A-769662 or another activator, 991 (also known as ex229 [30]), was 136	  
bound at the opposite surface of the β-CBM, in the cleft between it and the α-KD N-lobe; this cleft 137	  
is labeled in Fig. 2 although unoccupied. A-769662 and 991 are synthetic molecules, but the natural 138	  
plant product and AMPK activator, salicylate, was suggested to bind at the same site [31]; this was 139	  
recently confirmed by a crystal structure containing bound 5-iodosalicylate [13]. Salicylate (in the 140	  
form of willow bark extracts) has been used as a medicine since ancient times, with acetyl salicylic 141	  
acid (aspirin) being a synthetic derivative that is rapidly broken down to salicylate in vivo. 142	  
However, this leaves open the question as to whether there is a naturally occurring metabolite in 143	  
mammals that regulates AMPK by binding this site. Although such a metabolite has not yet been 144	  
found, the site has been referred to as the allosteric drug and metabolite (ADaM) binding pocket 145	  
[32]. 146	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Non-canonical inputs – activation by the Ca2+/CaMKKβ pathway 147	  
Hormones that increase intracellular Ca2+ activate AMPK via phosphorylation of Thr172 by the 148	  
calmodulin-dependent protein kinase CaMKKβ (Fig. 1) [33-35]. This represents an alternate, Ca2+-149	  
dependent pathway for AMPK activation that is independent of changes in adenine nucleotides and 150	  
is therefore considered to be non-canonical. However, because AMP binding inhibits Thr172 151	  
dephosphorylation, the two pathways can act synergistically [36].	  152	  
Indirect mechanisms for AMPK activation 153	  
Most other activators (Fig. 4C) activate AMPK indirectly by inhibiting ATP synthesis, thus 154	  
increasing intracellular AMP:ATP and ADP:ATP ratios [37]. These include the glycolytic inhibitor 155	  
2-deoxyglucose, the anti-diabetic drugs metformin and phenformin, and many natural plant 156	  
products that are either used in traditional medicines or are being tested for health-promoting 157	  
activities (e.g. berberine [38], arctigenin [39], and resveratrol [40]). Another interesting activation 158	  
mechanism is displayed by the tetrahydrofolate analogs pemetrexed and methotrexate, used for 159	  
treatment of cancer or inflammatory disorders such as rheumatoid arthritis. These analogs inhibit 160	  
tetrahydrofolate-utilizing enzymes, including the transformylase that catalyzes the first step in the 161	  
metabolism of ZMP, the phosphorylated form of AICAR, to purine nucleotides (although inhibition 162	  
by methotrexate is most likely secondary to inhibition of dihydrofolate reductase [41]). They 163	  
therefore cause accumulation of cellular ZMP, which binds to the γ subunit and activates AMPK 164	  
(Fig. 4D) [41, 42]. 165	  
Outputs: identification of downstream targets 166	  
Once AMPK is activated, it acts to restore energy homeostasis by activating catabolic pathways that 167	  
generate ATP and inhibiting anabolic pathways that consume ATP. However, since the great 168	  
majority of cellular processes consume energy and most are coupled to ATP hydrolysis, there is no 169	  
reason why processes switched off by AMPK should be restricted to metabolic roles. There has 170	  
therefore been a need to understand how AMPK recognizes its target phosphorylation sites, and to 171	  
develop methods to screen for, and even predict, novel downstream targets. This will form the 172	  
central theme of the remainder of this review, and some of the methods used are illustrated in Fig. 173	  
5. 174	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Initial hypothesis-driven approaches to determine the AMPK recognition motif 175	  
Sequencing of the first few sites phosphorylated by AMPK led to the identification of conserved 176	  
residues close to the phosphoacceptor site (P), including basic residues at P-3 and/or P-4 and 177	  
hydrophobic residues at P-5 and P+4, which were proposed to be important in recognition. This was 178	  
confirmed by making replacements within the SAMS peptide [43], which was based on the sequence 179	  
around Ser79 on rat acetyl-CoA carboxylase-1 (ACC1) and was the first peptide substrate for 180	  
AMPK [44]. This study also showed that AMPK would phosphorylate threonine, although serine 181	  
was preferred (this preference for serine is a feature of serine/threonine kinases in general). A 182	  
follow-up study utilized a specially designed peptide sequence (AMARAASAAALA) where all 183	  
residues other than the serine and the critical positions at P-5, P-3, and P+4 were alanine. This study 184	  
showed that the mammalian, budding yeast, and higher plant orthologs of AMPK had very similar 185	  
specificities, and that the position as well as the chemical nature of the P-5, P-3 and P+4 residues 186	  
was crucial, although the basic residue could be at P-4 or P-3 [45]. Another approach used a 187	  
bacterially expressed peptide containing 34 residues around the Ser79 site on rat ACC1 as the 188	  
substrate. A model for the binding of this sequence to the kinase domain was generated by 189	  
homology to structures of closely related kinases. By making complementary mutations of kinase 190	  
and substrate, and analyzing their effects on phosphorylation kinetics (Fig. 5A), this model was 191	  
validated [46]. An additional positive determinant identified in this study was a basic residue at P-6, 192	  
although not all known AMPK substrates contain this. This study also suggested that the sequence 193	  
N-terminal to P-5 in ACC1, in which conserved hydrophobic residues occur every 3-4 residues (at 194	  
P-5, P-9, P-13 and P-16), form an amphipathic α-helix that fits into a hydrophobic groove within 195	  
the C lobe of the α-KD. Interestingly, a partial structure of another AMPK target, HMG-CoA 196	  
reductase [47], revealed that residues from Gly860 to Arg871 (corresponding to P-12 to P-1 with 197	  
respect to the phosphorylation site, Ser872) do form such an α-helix. However, this amphipathic 198	  
helix cannot be essential for target recognition, because it is not present in the peptide substrates, or 199	  
in the liver or muscle isoforms of glycogen synthase, two well-validated targets for AMPK where 200	  
the P-6 residues actually form the N-termini of the mature proteins. These α-helices should 201	  
therefore be regarded as docking sites that enhance the affinity of the kinase-substrate interaction, 202	  
rather than as essential determinants for substrate recognition. 203	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Unbiased approaches to determine the recognition motif 204	  
The studies described in the previous section were built on hypotheses about substrate recognition 205	  
derived from sequences of a relatively small number of known targets. More recently, unbiased 206	  
screens to identify the preferred AMPK recognition motif have been developed. The first was a 207	  
peptide library approach using spatially arrayed sets of peptide mixtures [48], a method originally 208	  
developed for studies of other kinases [49]. Each mixture contained a fixed amino acid at a given 209	  
position relative to a central fixed serine/threonine phosphoacceptor, with mixtures at all other 210	  
positions (Fig. 5B). From the relative amount of phosphate incorporated into each mixture, a 211	  
measure of selectivity for and against individual amino acids at each position was obtained. 212	  
Gratifyingly, the results yielded a recognition motif remarkably similar to the earlier approaches, 213	  
with hydrophobic side chains being preferred at P-5 (especially M or L) and P+4 (I, L, M or F), and 214	  
basic side chains (R>K) at the P-4 or P-3 position; a preference for polar side chains at P+3 was 215	  
also noted [48]. One drawback of this approach is that it is not feasible to study the effects of amino 216	  
acids more than about five residues away from the phosphoacceptor, because the peptide mixtures 217	  
become too degenerate. 218	  
 A second method, represented in Fig. 5C, involved identification of large numbers of direct 219	  
targets in intact cells and allowed analysis beyond the P-5 and P+4 positions [50]. This approach 220	  
utilized a method where the ATP binding pocket of the kinase was enlarged by mutation to accept a 221	  
bulky (N6-phenethyl) derivative of ATP containing γ-thiophosphate. The bulky nucleotide was 222	  
introduced into intact cells through digitonin permeabilization and was used by the mutant kinase to 223	  
thiophosphorylate direct targets [51, 52]. The thiophosphorylated substrates were then 224	  
immunoprecipitated using a thiophosphate-specific antibody, resulting in identification of 28 new 225	  
targets	  [50]. This initial approach did not identify the actual phosphorylation sites, but the known 226	  
AMPK recognition motif was used to predict the phosphorylation sites on four (PPP1R12C, 227	  
BAIAP2, CDC27 and PAK2), which were subsequently independently validated [50]. 228	  
 Since existing AMPK recognition motifs were used in this approach to identify the likely sites, 229	  
sites that did not adhere to these motifs would have been missed. Another drawback was that it 230	  
might identify as false positives proteins that co-precipitated with the thiophosphorylated substrates. 231	  
A recent refinement of this method allows concurrent identification of both the substrate and its 232	  
thiophosphorylation site(s): the thiophosphorylated proteins are digested with trypsin and the 233	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modified peptides isolated via a peptide capture approach, allowing the sites to be directly identified 234	  
by tandem mass spectrometry [53]. When applied to AMPK (Fig. 5C) [54], the 32 phosphorylation 235	  
sites (27 of them novel) most frequently identified across replicate screens showed striking 236	  
resemblance to the established AMPK phosphorylation motif [43, 45, 46, 48]. Hydrophobic 237	  
residues (L, M, I) were observed at P-5, basic residues (R>K), usually at P-3 but also occasionally 238	  
at P-4 or P-2, neutral polar residues (S, N, T, Q) at P-2, polar and/or charged residues (S, D, N) at 239	  
P+3, and hydrophobic residues (usually L) at P+4 [54]. As suggested by an earlier approach [46], a 240	  
subset of sites contained basic residues at P-6, although they were not present at all sites. Some of 241	  
the novel sites [54], as well as many established AMPK target sites  (see supplementary Table 1 for 242	  
an updated list of 64 well-validated AMPK target sites, and Fig. 6), contain proline at P+2, which is 243	  
not selected in screens utilizing cell-free assays [48]. This is most likely due to the functional 244	  
overlap between AMPK phosphorylation motifs and 14-3-3 binding sites, with the latter usually 245	  
having a phosphoserine with R at P-3, S at P-2, and P at P+2 [55]. No strong distal motif outside of 246	  
P-5 to P+4 emerged from analysis of the phosphorylation sites identified in this study [54] or of 64 247	  
well-validated AMPK sites (supplementary Table 1), suggesting that the primary recognition motif 248	  
is contained within this window. It should also be noted that the target sequences listed in 249	  
supplementary Table 1 that were used to generate Fig. 6 excluded autophosphorylation sites, such 250	  
as Ser108 on AMPK-β1 [56], Ser491 on AMPK-α2 [57] , and several others [58]. While they can 251	  
have critical functions, autophosphorylation sites do not always conform to the recognition motif 252	  
found on other substrates, perhaps because their close proximity to the kinase domain means that 253	  
this is not necessary. 254	  
Prediction of novel targets using the AMPK recognition motif 255	  
AMPK now has a recognition motif (Fig. 6) that is among the best defined of any protein kinase, 256	  
making it potentially useful for predicting novel targets. It is important to note, however, that there 257	  
are likely to be many sites that conform to this motif that are not targets for AMPK, either because 258	  
they are not accessible to the kinase due to some aspect of structure or protein:protein interaction, or 259	  
because of their subcellular location. Since important phosphorylation sites are likely to be 260	  
conserved, several groups have searched protein databases to find motifs matching earlier versions 261	  
of the recognition motif, and then filtered their results by evolutionary conservation. This led to the 262	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identification of phosphorylation sites with important regulatory functions on RAPTOR [48], ULK1 263	  
[59], Class IIA histone deacetylases [60], and AMOTL1, the latter involved in Hippo signaling 264	  
[61]. Since AMPK phosphorylation often triggers 14-3-3 binding, the identification of some of 265	  
these was aided by screening for candidates that bound 14-3-3 proteins in an AMPK-dependent 266	  
manner. Recently, a similar analysis was conducted, searching for motifs in the proteome 267	  
containing basic residues at P-6 and P-4 and hydrophobic residues at P-5 and P+4, and several sites 268	  
predicted were validated as AMPK targets in cell-free assays [62]. In a parallel approach, an 269	  
antibody recognizing the core recognition motif (LxRxxpS/pT) was used to immunoprecipitate 270	  
proteins following AMPK activation in hepatocytes, which were then identified by mass 271	  
spectrometry. The majority of the proteins identified did contain that motif, and several of these 272	  
were validated as AMPK targets [63].  273	  
 These successes suggest that it should be possible to explore the full network of AMPK 274	  
substrates, and several resources for this are available. The motif prediction platform Scansite [64] 275	  
(http://scansite.mit.edu) provides a position weight matrix (PWM)-based algorithm for querying a 276	  
single protein, or a predefined protein database, for optimal AMPK motifs. Building on this, two of 277	  
us [54] developed an AMPK motif prediction platform (available at 278	  
https://github.com/BrunetLabAMPK/AMPK_motif_analyzer) by constructing a PWM from a list of 279	  
substrates, which contains the frequencies of each amino acid at each position in the motif from P-5 280	  
to P+4, and controls for a background of general phosphorylation motifs. The platform allows users 281	  
to upload tab-delimited files, and the output retains all data associated with each scored site. Thus, 282	  
large quantitative phosphoproteomic datasets can be queried for AMPK-like sites. The PWM can 283	  
also be used independently in other web-accessible platforms, such as FIMO [65] or Scansite to 284	  
query entire proteomes or other databases. In addition, the consensus motif may be used to identify 285	  
the likely AMPK phosphorylation sites on the many proteins that have been identified as in 286	  
substrate screens [50, 66] or as AMPK interacting proteins, as some of the latter may also be direct 287	  
AMPK targets [67, 68]. 288	  
 Finally, it might be worth noting that AMPK does seem to tolerate a little more flexibility in its 289	  
recognition motif than many other protein kinases. Thus, it will accept histidine rather than arginine 290	  
or lysine as the basic residue at P-3 or P-4, which many other “Basophilic” kinases do not. 291	  
Moreover, it appears to accept a little slippage in the exact position of the hydrophobic residue at P-292	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5. Thus, in NOS1, NOS3, PAK2 and PFKFB2 the hydrophobic residue is at P-4 rather than P-5, 293	  
although in all these cases it is followed by an arginine at P-3 (Supplementary Table 1). 294	  
Concluding remarks 295	  
Some important unresolved issues regarding the inputs and outputs impinging on AMPK are 296	  
outlined in the “Outstanding questions” Box. AMPK is now known to be activated through a 297	  
variety of upstream inputs, including the canonical mechanism involving sensing of adenine 298	  
nucleotide ratios, and non-canonical mechanisms such as those used by compounds that bind at the 299	  
ADaM site, and the Ca2+-dependent pathway involving CaMKKβ.   300	  
 The number of outputs, i.e. identified downstream targets, is also expanding rapidly. The 301	  
availability of phosphorylation site prediction tools should greatly assist in elucidation of the 302	  
complete network of downstream targets. However, the current site prediction tools do have some 303	  
limitations. AMPK-α1 and -α2 lie in the same branch of the kinome as up to twelve AMPK-related 304	  
kinases, and some of the latter, notably the MARKs [69], have similar recognition motifs. Thus, 305	  
using the AMPK recognition motif to predict sites may also yield targets for AMPK-related kinases. 306	  
Covalent modifications within the proximity of the target site (such as oxidation of methionine 307	  
when this is the hydrophobic residue at P-5 [70]) might also affect recognition. In addition, 308	  
sequences and/or higher order structures outside of the P-5 to P+4 window, such as the amphipathic 309	  
helix from P-15 to P-5 upstream of Ser79 on ACC1, can enhance the recognition of specific sites. 310	  
Because these are not essential, the increased power they could bring to site prediction is currently 311	  
lost. One future direction might be to investigate whether multiple subsets of distal recognition 312	  
motifs exist, which might contain elements that increase predictive power. Further exploration of 313	  
the network in different contexts, for example when activated by different inputs, will be a key step 314	  
in better understanding the physiological and pathological roles of this central energy-sensing 315	  
kinase. 316	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FIGURE LEGENDS 325	  
Figure 1: Canonical mechanism of activation of AMPK by adenine nucleotides, and the 326	  
Ca2+-dependent mechanism mediated by CaMKKβ . AMP binding activates AMPK 327	  
by three effects, i.e. promotion of Thr172 phosphorylation by LKB1 (effect #1), 328	  
inhibition of Thr172 dephosphorylation by protein phosphatases (PP) (effect #2), and 329	  
allosteric activation (effect #3). All three effects are opposed by binding of ATP, while 330	  
binding of ADP mimics effect #2 and #1, but not #3. CaMKKβ phosphorylates the 331	  
same site as LKB1 (Thr172) in response to increases in cellular Ca2+. 332	  
Figure 2: Crystal structure of the human α1β2γ1 heterotrimer in complex with β-333	  
cyclodextrin, staurosporine, and AMP, with Thr172 phosphorylated. Atomic co-334	  
ordinates are from the PDB file 4RER [8]. The model was rendered in PyMOL v1.7.4.2 335	  
with the majority of the polypeptide in “cartoon” view and the α-linker in “sphere” 336	  
view. The domains referred to in the text are color coded and labeled. The kinase 337	  
inhibitor staurosporine in the active site, and the side chain of phospho-Thr172, are in 338	  
“sphere” view, and β-cyclodextrin in the glycogen-binding site of the β-CBM in “stick” 339	  
view, all with C atoms in green, O red, and N blue (H omitted).  The curved dotted line 340	  
in the center shows the approximate boundary between the “catalytic module” 341	  
(containing the α-KD and β-CBM) and the “nucleotide-binding module” (containing 342	  
the γ subunit and the C-terminal domains of α and β); the α-AID and α-linker form one 343	  
of the flexible connectors linking these two modules. Note how the α-RIM2 section of 344	  
the α-linker (in magenta) contacts site 3 of the γ subunit with its bound AMP. 345	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Figure 3: Structures of the kinase domain (α-KD) and auto-inhibitory domains (α-AID) of 346	  
the α  subunit in (A) inactive and (B) active conformations. Atomic co-ordinates are 347	  
from the PDB files 4RED (A) and 4RER (B) [8], with only the α-KD, α-AID and the 348	  
start of the α−linker being displayed in (B). The color-coding of domains is as in Fig. 2. 349	  
Most of the structures are rendered in “cartoon” view (PyMOL v1.7.4.2), but the side 350	  
chains of the regulatory spine [18] (Leu81, white; Leu70, red; Phe160, magenta; 351	  
His139, blue), and phosphorylated Thr172 in (B), are in “sphere” view. Note how the 352	  
residues of the regulatory spine are stacked in alignment in (B) but not in (A). In (A), 353	  
the α-AID shown is that attached to the other molecule of α-KD:α-AID within the 354	  
crystal dimer, but in solution the α-AID from the same molecule is thought to adopt this 355	  
position [8]. 356	  
Figure 4: Selection of AMPK activating compounds grouped according to their mechanisms 357	  
of action. (A) pro-drugs converted into AMP analogs by cellular enzymes; (B) 358	  
compounds that bind at the ADaM site; (C) compounds that act by inhibiting 359	  
mitochondrial ATP synthesis and thus increase cellular AMP and ADP; (D) antifolate 360	  
drugs that activate AMPK by inhibiting AICAR transformylase in the pathway of 361	  
purine nucleotide biosynthesis (shown), thus increasing cellular ZMP. Figure modified 362	  
from Fig. 1 in [71].  363	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Figure 5: Approaches used to characterize the AMPK recognition motif. (A) Hypothesis-364	  
driven approach using mutations. Constructs containing 34 residues around Ser79 on 365	  
ACC1, with and without the indicated mutations, were expressed in bacteria and 366	  
phosphorylated by AMPK in cell-free assays. Changes in kinetic parameters (kcat/Km) 367	  
for each mutant relative to the wild type are represented by the lengths of the bars above 368	  
(increases) or below (decreases) the indicated amino acid [46]. (B) Positional scanning 369	  
peptide library. Phosphorylation by AMPK in cell-free assays of peptide mixtures (10-370	  
mers) containing serine and threonine at position 6, a fixed amino acid at one position 371	  
(e.g. P-5, illustrated), and random mixtures at all others, revealed preferences for 372	  
specific amino acids at each position [48]; “x”, any amino acid. (C) Direct 373	  
thiophosphorylation with gatekeeper mutation. An AMPK mutant uses a bulky 374	  
derivative of ATP-γ−S (A*TPγS) to thiophosphorylate direct targets in permeabilized 375	  
cells [50]. Many direct AMPK phosphorylation sites were identified through isolation 376	  
and identification by tandem mass spectrometry of the thiophosphorylated peptides 377	  
[54]. Hydrophobic amino acids are in green, neutral polar in blue, acidic in orange, and 378	  
basic in red. 379	  
 380	  
Figure 6: AMPK recognizes a well-defined phosphorylation motif. The logo motif of 64 381	  
known AMPK phosphorylation sites from P-7 to P+7 is presented, and points of interest 382	  
in the AMPK recognition motif are noted. Color scheme as in Figure 5. The logo motif 383	  
was generated by WebLogo [72], using a previously described list of 50 well-validated 384	  
phosphorylation sites [54] updated with 14 additional sites from the literature. This full 385	  
list of 64 well-validated AMPK targets is provided as supplementary Table 1. Human 386	  
sequences were used to generate this motif. 387	  
  388	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Glossary: 389	  
α-AID: auto-inhibitory domain, the domain that follows the kinase domain in AMPK-α subunits, 390	  
and which inhibits the kinase domain in the absence of AMP 391	  
α-KD: kinase domains on the α subunits of AMPK, which are related to the catalytic domains in 392	  
other members of the “eukaryotic” protein kinase (ePK) family 393	  
α-linker: region of the AMPK-α subunit that connects the α-AID to the C-terminal domain, 394	  
important in the mechanism of regulation by AMP 395	  
α-RIM1/α-RIM2: conserved sequences within the α-linker, which interact with the AMPK-γ 396	  
subunit when AMP is bound at site 3 397	  
ADaM site: the “Allosteric Drug and Metabolite” binding pocket, located between the α subunit 398	  
kinase domain and the β subunit carbohydrate-binding module, where drugs such as A-769662 399	  
bind, and where naturally occurring metabolites are speculated to bind 400	  
CBS repeat: a sequence motif, first found in the enzyme cystathionine β-synthase, that always 401	  
occurs as tandem repeats; a single twin repeat often binds a ligand containing adenosine, such as 402	  
AMP, ATP or S-adenosylmethionine 403	  
kinase recognition motif: amino acid sequence surrounding a phosphorylation site, which 404	  
promotes a given protein kinase to target that residue 405	   	    406	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A) Pro-drugs converted within cells to AMP analogs
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C) Compounds that inhibit mitochondrial ATP synthesis and increase cellular AMP
































Standardize amino acid 
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adapted from Scott et al, 2002
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B. Positional scanning peptide library
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4. Analysis of direct AMPK substrate motif
adapted from Banko et al, 2011 and Schaffer et al, 2015
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P, K, and H at 
P-6 may be
important in
a subset of 
motifs
V and F not as 
prominent at P-5 
as L, M, and I
Basic residue, notably R,
preferred at P-3, but there 
is flexibility in basic residue 
location
P not selected for in 
cell-free assays, may be 
functional overlap with 
14-3-3 binding motif
More apparent 
flexibility in which 
hydrophobic residue 
is located at P+4 
than P-5 
AMPK may prefer 
polar side chains at 
P+3 in some motifs 
S preferred over T as 
phosphorylated residue
S, T, R, and V 
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Table S1: List of 64 validated sites phosphorylated by AMPK.  	  
Short name Long name UNIPROT Sitea Motif (± 10 residues)b Criteriac Refs 
1d 2e 3f 4g 
ACACA Acetyl-CoA carboxylase 1 Q13085 S80 GLALHIRSSMSGLHLVKQGRD X X  X [3-6] 
ACACB Acetyl-CoA carboxylase 2 O00763 S222 TRVPTMRPSMSGLHLVKRGRE X X   [7-10]  
AMOTL1 Angiomotin-like protein 1 Q8IY63 S793 TDSSSLRPARSVPSIAAATGT X X   [11] 
BAIAP2 Brain angiogenesis inhibitor 1-associated protein 2 Q9UQB8 S366 TENKTLPRSSSMAAGLERNGR X  X X [1] 
BRAF Serine/threonine-protein kinase B-raf P15056 S729 RSLPKIHRSASEPSLNRAGFQ X X   [12] 
CDC27 Cell division cycle protein 27 homolog P30260 S379 SPPNALPRRSSRLFTSDSSTT X  X  [1] 
CDC42EP1 Cdc42 effector protein 1 Q00587 S192 PSEPGLRRSDSLLSFRLDLDL   X X [2] 
CDKN1B Cyclin-dependent kinase inhibitor 1B P46527 T198 PKKPGLRRRQT X X   [13] 
CLIP-170 CAP-Gly domain-containing linker protein 1 P30622 S312 TTSASLKRSPSASSLSSMSSV X X   [14] 
CRTC2 CREB-regulated transcription coactivator 2 Q53ET0 S171 RLPSALNRTSSDSALHTSVMN X X   [15-18] 
CRY1 clock component cryptochrome 1 Q16526 S71 DLDANLRHLNSRLFVIRGQPA X X   [19] 
EEF2K eukaryotic elongation factor 2 kinase O00418 S398 VTFDSLPSSPSSATPHSQKLD X X   [20] 
EP300 Histone acetyltransferase p300 Q09472 S89 KQLSELLRSGSSPNLNMGVGG X X   [21, 22] 
FOXO3a Forkhead box protein O3 O43524 S413 PTGGLMQRSSSFPYTTKGSGL X X   [23] 
FOXO3a Forkhead box protein O3 O43524 S588 QSMQTLSDSLSGSSLYSTSAN X X   [23] 
GABABR2 GABA B receptor R2 subunit O75899 S784 STSVTSVNQASTSRLEGLQSE X X   [24] 
GBF1 Golgi-specific brefeldin A-resistance GEF-1 Q92538 T1337 GRPGKIHRSASDADVVNSGWL X X   [25] 
GFPT1 Glutamine-fructose-6-phosphate aminotransferase-1 Q06210 S261 KGSCNLSRVDSTTCLFPVEEK X X   [26, 27] 
GLI1 Zinc finger protein GLI1 P08151 S102 SLDLQTVIRTSPSSLVAFINS X X   [28] 
GLI1 Zinc finger protein GLI1 P08151 S408 RGDGPLPRAPSISTVEPKRER X X   [28] 
GLI1 Zinc finger protein GLI1 P08151 T1074 SHDQRGSSGHSPPPSGPPNMA X X   [28] 
GYS1 Glycogen Synthase 1 (muscle isoform) P13807 S8    MPLNRTLSMSSLPGLEDW X X   [29, 30] 
GYS2 Glycogen Synthase 2 (liver isoform) P54840 S8    MLRGRSLSVTSLGGLPQW X X   [31] 
H2B Histone H2B Q16778 S37 GKKRKRSRKESYSIYVYKVLK X X   [32] 
HDAC5 Histone Deacetylase 5 Q9UQL6 S259 RDDFPLRKTASEPNLKVRSRL X X   [33] 
HDAC5 Histone Deacetylase 5 Q9UQL6 S498 PRHRPLSRTQSSPLPQSPQAL X X   [33] 
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme A reductase P04035 S872 LVKSHMIHNRSKINLQDLQGA X    [34-36] 
IRS1 insulin receptor substrate 1 P35568 S794 ARHQHLRLSTSSGRLLYAATA X X   [37, 38] 
KCNB1 Potassium voltage-gated channel subfamily B member 1 Q14721 S444 EALERAKRNGSIVSMNMKDAF X X   [39] 
KCNB1 Potassium voltage-gated channel subfamily B member 1 Q14721 S541 DMYNKMAKTQSQPILNTKESA X X   [39] 
KLC2 Kinesin light chain 2 Q9H0B6 S545 DGSGSLRRSGSFGKLRDALRR X   X [40, 41] 
LIPE Hormone-sensitive lipase Q05469 S855 PIAEPMRRSVSEAALAQPQGP X    [42-44] 
MAPT Microtubule-associated protein tau P10636 S579 DLKNVKSKIGSTENLKHQPGG X X   [45, 46] 
MDM4 Mdm4 O15151 S342 SDCSKLTHSLSTSDITAIPEK X X   [47] 
NET1 Neuroepithelial cell-transforming gene 1 protein Q7Z628 S100 KRVRPLARVTSLANLISPVRN  X X X [2] 
NOS1 Neuronal nitric oxide synthase (nNOS) P29475 S1417 YEVTNRLRSESIAFIEESKKD  X   [8, 48] 
NOS3 Endothelial nitric oxide synthase (eNOS) P29474 S1177 QEVTSRIRTQSFSLQERQLRG X    [49] 
PAK2 Serine/threonine-protein kinase PAK 2 Q13177 S20 KPPAPPVRMSSTIFSTGGKDP X X X  [1] 
PEA15 Astrocytic phosphoprotein PEA-15 Q15121 S116 KKYKDIIRQPSEEEIIKLAPP X X   [50] 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 O60825 S466 NQTPVRMRRNSFTPLSSSNTI X X   [51] 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 Q16875 S461 KGPNPLMRRNSVTPLASPEPT X X   [52, 53] 
PGC1A PPAR-gamma coactivator 1-alpha  Q9UBK2 T178 NHANHNHRIRTNPAIVKTENS X X   [54] 
PGC1A PPAR-gamma coactivator 1-alpha  Q9UBK2 S539 QSYSLFNVSPSCSSFNSPCRD X X   [54] 
PIKFYVE 1-phosphatidylinositol 3-phosphate 5-kinase Q9Y2I7 S307 GKSPARNRSASITNLSLDRSG X X   [55] 
PLD1 Phospholipase D1 Q13393 S505 TDVGSVKRVTSGPSLGSLPPA X X   [56] 
PPP1R12C Protein phosphatase 1 regulatory subunit 12C Q9BZL4 S452 APGAGLQRSASSSWLEGTSTQ X X X  [1] 
PRKCQ protein kinase C-theta Q04759 T538 ENMLGDAKTNTFCGTPDYIAP X X   [57] 
RAG1 V(D)J recombination-activating protein 1 P15918 S531 EWQPPLKNVSSSTDVGIIDGL X X   [58] 
RPTOR Regulatory-associated protein of mTOR Q8N122 S792 ETIDKMRRASSYSSLNSLIGV X X   [59] 
RPTOR Regulatory-associated protein of mTOR Q8N122 S722 PCTPRLRSVSSYGNIRAVATA    X [59] 
RRN3 RNA polymerase I-specific transcription initiation factor Q9NYV6 S635 SSFDTHFRSPSSSVGSPPVLY X X   [60] 
SNX17 Sorting nexin-17 Q15036 S437 ESMVKLSSKLSAVSLRGIGSP  X X X [2] 
SREBF1 Sterol regulatory element-binding protein 1 P36956 S396 SLRTAVHKSKSLKDLVSACGS X X   [61] 
TBC1D1 TBC1 domain family member 1 Q86TI0 S237 PVRRPMRKSFSQPGLRSLAFR X X  X [62] 
TBC1D4 TBC1 domain family member 4 O60343 S704 SSLPSLHTSFSAPSFTAPSFL X X   [63] 
TNNI3 Troponin I, cardiac muscle P19429 S150 KRPTLRRVRISADAMMQALLG X X   [64, 65] 
TP53 p53 P04637 S15 QSDPSVEPPLSQETFSDLWKL X X   [66, 67] 
TP73 Tumor protein p73 O15350 S426 KVHGGMNKLPSVNQLVGQPPP X    [68] 
TSC2 tuberous sclerosis complex 2 P49815 S1387 QPSQPLSKSSSSPELQTLQDI X X   [69] 
TXNIP Thioredoxin-interacting protein Q9H3M7 S308 SRSGLSSRTSSMASRTSSEMS X X   [70] 
ULK1 Serine/threonine-protein kinase ULK1 O75385 S467 PRSSAIRRSGSTSPLGFARAS X X   [71] 
ULK1 Serine/threonine-protein kinase ULK1 O75385 S556 RTSGLGCRLHSAPNLSDLHVV X X   [71] 
VASP Vasodilator-stimulated phosphoprotein P50552 T278 NAMLARRRKATQVGEKTPKDE X X   [72] 
YAP1 Transcriptional coactivator YAP1 P46937 S94 VPMRLRKLPDSFFKPPEPKSH X X   [73] 
aPhosphorylation site (human sequence numbering) 
bPhosphorylation site motif ±10 residues upstream and downstream of the phosphoamino acid 
Red = phosphorylated serine/threonine; brown = bulky hydrophobic residues ((L, I, M, F, V)) at P-5 and P+4; and blue = basic residues at P-6, P-4, P-3 
or P-2. In some cases, N-terminal hydrophobic and basic residues are shifted one residue from these standard locations (see main text); these are also 
color coded. Where no residues are shown, the site is near the N- or C-terminus of the protein.  
cCriteria that were used to validate AMPK substrates. In general, a site can be considered a well-validated AMPK substrate when both a direct 
phosphorylation in cell-free assays and AMPK-dependent phosphorylation in intact cells have been demonstrated in a site-specific manner (criteria 1 
and 2 together), or the site was identified and validated using the ATP-analog-specific approach in intact, permeabilized cells. In this list, we have 
generally not taken into account evidence obtained using functional changes in the target protein. Given the size of the AMPK literature, we did not 
include all sites that have been exclusively validated in cell-free assays, and we may have missed some key substrates or data relevant to the validation 
of some listed substrates. 
dcell-free assays demonstrating that AMPK directly phosphorylates the site in question (e.g. via mass spectrometry, 32P incorporation or 
phosphospecific antibodies, preferably with comparisons of phosphorylation with and without mutation at the site) 
eDemonstration that AMPK phosphorylates the site in intact cells through either; (i) increases in phosphorylation in response to treatment with specific 
AMPK activators (e.g. A769662, AICAR, 991); (ii) decreases in phosphorylation following knockout or knock-down (e.g. by expression of dominant 
negative AMPK mutant or interfering RNA); or (iii) the use of less specific AMPK activators (e.g. 2-deoxyglucose, metformin, muscle contraction) in 
combination with AMPK knockdown or inhibition (e.g. using compound C, although the authors discourage the use of that compound, which is a very 
non-selective kinase inhibitor). 
fDemonstration that ATP analog-specific (AS) AMPK thiophosphorylates the specific site in intact permeabilized cells [1]. 
gIdentification of the site with high confidence in Schaffer et al [2].  
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Glossary: 
α-AID: auto-inhibitory domain, the domain that follows the kinase domain in AMPK-α subunits, 
and which inhibits the kinase domain in the absence of AMP 
α-KD: kinase domains on the α subunits of AMPK, which are related to the catalytic domains in 
other members of the “eukaryotic” protein kinase (ePK) family 
α-linker: region of the AMPK-α subunit that connects the α-AID to the C-terminal domain, 
important in the mechanism of regulation by AMP 
α-RIM1/α-RIM2: conserved sequences within the α-linker, which interact with the AMPK-γ 
subunit when AMP is bound at site 3 
CBS repeat: a sequence motif, first found in the enzyme cystathionine β-synthase, that always 
occurs as two tandem repeats; a single twin repeat often binds a ligand containing adenosine, 
such as AMP, ATP or S-adenosylmethionine 
kinase recognition motif: amino acid sequence surrounding a phosphorylation site, which 
promotes a given protein kinase to target that residue 	  
TRENDS:	  
• AMPK is an energy-sensing protein kinase activated by phosphorylation of Thr172 within its 
catalytic α subunit. It binds AMP and/or ADP, both signals of energy stress, via its regulatory 
γ subunit. This activates the kinase by promoting Thr172 phosphorylation, inhibiting Thr172 
dephosphorylation and allosteric activation. 
• AMP binding to the γ subunit causes its interaction with the “α-linker” region of the α subunit. 
This pulls the auto-inhibitory domain on the α subunit away from the kinase domain, triggering 
activation. 
• AMPK is also activated by binding of synthetic and naturally occurring drug-like molecules that 
bind in the allosteric drug and metabolite (ADaM) site, between the α and β subunits 
• AMPK has a well-defined recognition motif that has been established both by hypothesis-driven 
approaches and by various unbiased screens. It now has over 60 well-validated substrates. 	  
Outstanding questions: 
1. Given that site 3 on the AMPK-γ subunit seems to be the crucial site where binding of AMP 
causes activation, what is the function of AMP binding at the other two sites, sites 1 and 4? 
2. How does binding of AMP or ADP to the AMPK-γ subunit promote phosphorylation of the 
AMPK-α subunit at Thr172 by upstream kinases such as LKB1? 
3. Are there any naturally occurring metabolites in mammalian cells that bind to the allosteric drug 
and metabolite (ADaM) binding pocket between the α and β subunits, and thus activate or 
inhibit AMPK? 
4. How are responses to different inputs affected by the numerous post-translational modifications 
that have been reported to occur on each AMPK subunit? 
5. Does AMPK phosphorylate a different subset of substrates, depending on the inputs via which it 
was activated? 
6. Are there subsets of primary or secondary structures, beyond the defined window from amino 
acids -5 to +4 in the AMPK recognition motif, which can help better predict substrates? 
7. How much flexibility is there in the recognition motif surrounding any given AMPK 
phosphorylation site? For example can more distal features, such as the N-terminal amphipathic 
α-helices that are observed in acetyl-CoA carboxylase and HMG-CoA reductase, determine how 
rigidly the motif from P-5 to P+4 must adhere to the canonical recognition motif? 	  
